Aprogen Turns To IPO To Support Biosimilar Pipeline Expansion
This article was originally published in PharmAsia News
Executive Summary
South Korea's Aprogen, which has reached global partnership with Japan's Nichi-Iko for development of its biosimilar versions of Remicade, Herceptin and Rituxan/Mab Thera, is seeking to independently conduct clinical development of other biosimilar products by using the proceeds from its domestic initial public offering.